key: cord-0853841-39beahss
authors: Tandon, Medha; Kataria, Saurabh; Patel, Jenil; Mehta, Tejas R.; Daimee, Maha; Patel, Viral; Prasad, Apoorv; Chowdhary, Anisa Anila; Jaiswal, Shruti; Sriwastava, Shitiz
title: A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19
date: 2021-01-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.01.002
sha: dfe1a2eb66c771d54f284df778d3b9d48be9367e
doc_id: 853841
cord_uid: 39beahss

BACKGROUND: Limited literature exists on CSF findings in COVID-19 patients with neurological symptoms. In this review, we conducted a descriptive analysis of CSF findings in patients with COVID-19 to understand prognosis and explore therapeutic options. METHODS: We searched PubMed, Google Scholar and Scopus databases using the keywords “SARS-CoV-2 in cerebrospinal fluid”, “SARS-CoV-2 and CNS Complications”" for reports of CSF findings in COVID-19 related neurological manifestations. Descriptive analysis were conducted to observe the CSF protein and cell counts based on age, gender, severity and fatality of COVID-19, and whether central (CNS) or peripheral nervous system (PNS). RESULTS: A total of 113 patients were identified from 67 studies. Of these, 7 patients (6.2 %) were fatal COVID-19 cases and 35 patients (31%) were considered severe COVID-19 cases. CSF protein was elevated in 100% (7/7) of the fatal cases with an average of 61.28 mg/dl, and in 65.0 % (52/80) in non-fatal cases with an average 56.73 mg/dl. CSF protein levels were elevated in 74.5% (38/51) patients with non-severe COVID-19 and 68.6% (24/35) in those with a severe COVID-19 infection. CSF cell count was increased in 43% of fatal cases, 25.7% severe cases and 29.4% of non-severe cases. CONCLUSION: Our analysis showed that the most common CSF picture in COVID-19 infection is elevated protein with very occasionally mild lymphocyte predominant pleiocytosis. Further studies to elucidate pathophysiology of neurological complications in COVID-19 are recommended.

The novel Coronavirus disease 2019 (COVID-19) pandemic continues to present clinical challenges worldwide. Since the beginning of the pandemic, neurological manifestations have been vastly described in patients with COVID-19 [1] [2] [3] .

In addition to specific central nervous system (CNS) and peripheral nervous system (PNS) symptoms, nonspecific neurological manifestations such as headache, myalgia, anosmia, hypogeusia, myopathy have been reported in patients with COVID-19 [4] . The spectrum of neurologic complications ranges from CNS involvement like meningitis/encephalitis, encephalopathy, stroke and PNS involvement like Guillian-Barre Syndrome (GBS) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .

The severity of the disease varies based on the virus nervous tissue tropism. Positive nasal swab test for the virus has not been correlated with the presence or absence of the virus in the CSF in patients with neurologic manifestations. Therefore, CSF analysis via lumbar puncture (LP) may should be considered in patients with confirmed COVID-19 in order to further understand the virus pathology [5, 11, 16, 17] [4, 10, 15, 16] . In general, neurologists tend to avoid doing an invasive J o u r n a l P r e -p r o o f and expensive procedure such as LP in patients with non-specific COVID-19 neurological symptoms.

It is currently not clear if the mechanism of injury is due to direct viral invasion into the CNS or inflammatory cytokine release induced by the virus leading to a cascade of immune cells within the CNS [1, [18] [19] [20] [21] [1, [17] [18] [19] [20] . The virus is potentially neurotropic, with spread via the systemic circulation or across the cribriform plate [20, 22] . ACE-2 receptors on the capillary endothelium may be the target for SARS-CoV-2 spike protein facilitating viral entry into the nervous system [20] . Infection of the CNS can cause manifestations such as anosmia, dysgeusia, and in more severe cases, encephalitis [20, 23] . In addition to direct viral invasion, the brain may be affected secondarily due to extensive endothelial dysfunction from cytokine storm that predisposes to arterial/venous thrombosis or hemorrhage and resultant stroke [22, 24] .

Parainfectious complications secondary to dysregulated immunity may lead to antibody-mediated damage to the central or peripheral nervous system leading to Bickerstaff's encephalitis and Guillain-Barré Syndrome (GBS) that was described in MERS-CoV. Prolonged ICU stay and mechanical ventilation may lead to critical care neuropathy/myopathy [25, 26] .

Other coronaviruses that have been studied demonstrated a combination of invasion of the CNS, damage to the neurons, and a cascade of inflammatory cycle [19, 27, 28] [18, 21, 22] . SARS-CoV-1 in mice showed expression of human ACE2 which was also found in human brain autopsies of infected patients [19] [18] . The same receptor specifically found in neurons has also been implicated in the pathogenesis of SARS-CoV-2 emphasizing a possible invasion of the CNS [20] [19] . -PCR for COVID-19, while the rest had negative CSF RT-PCR. Elevated CSF protein, lactate or WBCs with a negative COVID-19 PCR may indicate inflammatory changes seen in autoimmune encephalitis [11] [10] . A recent correspondence by Lucchese G. highlights that many recent systematic reviews of CSF analysis in patients with COVID-19 resulted in negative CSF RT-PCR, most likely due to autoimmunity [29] . The high frequency of anti-neuronal and anti-glial antibodies is remarkable. However, larger cohorts are needed to establish the understanding about these connections.

CSF analysis can be of utmost importance in patients with confirmed COVID-19 in order to further understand the virus pathology and to rule out other infectious or inflammatory pathology. We performed a literature review of CSF analysis in COVID 19 patients with neurological manifestations to understand if there is a common pattern of CSF findings. We tried to elucidate if there is a difference in pattern of CSF findings when looking at CNS versus PNS manifestations. We also explored the differences in CSF findings based on demographic characteristics and severity of COVID-19 to prognosticate patients with neurological complications.

We conducted a thorough literature review in August 2020 using the terms "SARS-CoV-2 in Finally, we screened 1076 articles for title and abstracts, and reviewed full-text literatures in accordance with our study objective after removing 2570 articles which were either missing clinical information, CSF data or did not meet our study objective. We included 67 articles for review for observational analysis ( Figure 1 ) based on data availability.

The inclusion criteria for the published studies comprised of: 1) Patient age ≥ 18 years; 2) COVID-19 diagnosis confirmed by RT-PCR nasopharyngeal or serum IgG antibody test; 3) CSF study findings available in COVID-19.

The exclusion criteria for the studies comprised of 1) Duplicate studies which involved repetition of cases; 2) Articles in languages other than English; 3) Studies that had no available individual patient's data; 4) Editorials

The critical appraisal checklist for case reports provided by the Joanna Briggs Institute (JBI) was used to perform assessment of overall quality of case series and case reports [31][24].

From the selected articles, we extracted the following data for our analysis: study type, date of publication, age, gender, clinical presentation of COVID-19, diagnostic tests for SARS-CoV-2 infection including RT-PCR nasopharyngeal and serum antibodies, CSF markers including cell J o u r n a l P r e -p r o o f count, lymphocytes percentage, protein, IL-6, severity of COVID-19 (based on IDSA/ATS criteria) [32] [25].

We reported demographics including age and gender, and severity of COVID-19 cases and fatality of the cases. Pooled descriptive analyses were conducted to assess differences in CSF protein and cell count markers based on demographic characteristics, COVID-19 severity, fatality, and whether CNS or PNS.

A total of 67 articles describing 113 patients were examined. There were 57 males and 29 females; sex was not reported for 27 patients. The mean age for the patients were 57.0 (SD=14.3).

The baseline characteristics for the patients is shown in Table 1 Table 2 1).

Cell count in CSF analysis was reported in 97 patients. We only considered the lymphocyte percentage in patients who had a cell count of >5 cells/µL. The value was reported in nine patients.

Only one patient reported lymphocyte percentage of 10% whereas the rest of the eight patients had lymphocyte percentage >80%. Out of these eight patients, six had CNS manifestations, one had PNS manifestations and one patient did not report any manifestation. All except for one case were non-severe and none of the eight cases where the outcome was reported were fatal.

The other CSF marker that we studied for the purpose of this study was IL-6 levels. This was reported in five patients. It was found to be elevated in two non-severe cases and three severe cases. Only one out of five fatal cases showed elevated IL-6 levels and three out of five non-fatal cases reported this finding. None of the cases with PNS manifestation had elevated IL-6 in their CSF while all five cases reported of elevated IL-6 with CNS manifestation. Table 3 2).

In this systematic review we describe findings of CSF analysis in COVID-19 patients with neurological manifestations. Our analysis reveals that the most common CSF picture in COVID- Table 3 ).

Since the elevated protein is noted in all spectrum of neurological manifestations including fatal, it cannot be used as a marker of prognosis. However, the similarity of CSF picture indicates J o u r n a l P r e -p r o o f that there might be only one common neuro-inflammatory pathophysiology responsible for the neurological manifestations of COVID-19 specially when the CSF findings are similar between CNS and PNS manifestations. Due to limited therapeutic options in COVID-19, CSF markers and protein levels could be used as a future guiding marker for treatment initiation with higher dose of steroids or another immunotherapy.

A recent study of 5 patients with persistent encephalopathy showed significant improvement with high dose steroids but their CSF findings did not show elevated protein or cell count [47] [40] . The trends noted in our observational study suggest that presence of SARS-CoV-2 in the CSF is highly variable and may depend on the turnover of the virus and the level of neuroinvasion. CSF IgM testing has shown variable results and cannot be relied upon as the sole marker for SARS-CoV-2 presence.

In our entire cohort, we found a total of 17 cases in which MRI imaging of brain and cranial nerves was reported. Amongst them, 6 (35%) had abnormal findings that inclusive of cranial nerve CN III, CN VI and CN VII enhancement [13, [48] [49] [50] [51] [52] . Apart from these, one case of leptomeningeal enhancement of brainstem and cervical spine was noted [48] . Moreover, MRI lumbar spine was also performed in 36% of the cases (18/50), out of which 5 (27%) were found to have abnormal lumbar spine nerve root enhancement and the remaining 73% (13/18) had normal spine imaging [12, 13, 15, 48] .

Our study had several limitations. First, the CSF analysis reported in the studies can be Our study might also suffer from a final limitation of lack of search from EMBASE and other databases. Despite these limitations, we believe the data considered in our study is truly representative of CSF findings in COVID-19 patients and helps provide a more comprehensive picture of this understudied topic.

More severe and fatal cases with neurological complications were associated with elevated protein as compared to non-severe and nonfatal cases, which can be a marker for CNS involvement. In patients with COVID-19 with neurological manifestations, a combination of SARS-CoV-2 serum and CSF RT-PCR, CSF IgM testing, and specific CNS targeting antibodies can be used together to guide diagnosis, management and outcomes prognosis. More studies including RCTs are needed to note the trend of the above-mentioned markers that may serve as biomarkers for diagnosis as well as prognostication of the neurological manifestations of SARS-CoV-2. The most common finding of CSF analysis was elevated CSF protein with occasionally 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J o u r n a l P r e -p r o o f

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Clinical features of patients infected with 2019 novel coronavirus in

Neurological complications in patients with SARS-CoV-2 infection: a systematic review

Effects of COVID-19 on the nervous system

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

COVID-19: a global threat to the nervous system

Neurologic Features in Severe SARS-CoV-2 Infection

Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke

COVID-19 and the nervous system

Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid

Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19

Guillain-Barre Syndrome Associated with SARS-CoV-2

Guillain-Barré Syndrome as a Neurological Complication of COVID-19 Infection: A Case Series and Review of the Literature

SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome

COVID-19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR

First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder

Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019

First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review

Novel coronavirus and central nervous system

A Case of COVID-19 Encephalitis

Allograft infiltration and meningoencephalitis by SARS-CoV-2 in

COVID-19-Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome

IgM Positive Patient 3= IL-8, 10: elevated; Anti-S1 IgM Positive

CNS manifestation includes -stroke (ischemic, hemorrhagic, dural sinus venous thrombosis, meningoencephalitis, encephalitis, encephalopathy, seizure, ADEM, Acute hemorrhagic necrotizing, CNS vasculitis, transverse myelitis. PNS manifestation includes-GBS, polyneuritis cranialis, facial nerve palsy Severity based on Infectious Diseases Society of America

Peripheral Nervous System

Acute disseminated Encephalomyelitis

We would like to thank Riddhi Patel MBBS, MPH, PhD(c) (UTHealth School of Public Health, Houston, TX) for providing assistance on the study. 8 Patient 1=1